The financing of drug trials by pharmaceutical companies and its consequences: Part 1. A qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials;Finanzierung von arzneimittelstudien durch pharmazeutische unternehmen und die folgen: Teil 1: Qualitative systematische literaturübersicht zum einfluss auf studienergebnisse, -protokoll und -qualität

Deutsches Arzteblatt

Volumn 107, Issue 16, 2010, Pages 279-285

  Schott, Gisela ^a   Pachl, Henry ^a   Limbach, Ulrich ^c   Gundert Remy, Ursula ^a   Ludwig, Wolf Dieter ^a,b   Lieb, Klaus ^c  

^a Arzneimittelkommission der Deutschen Ärzteschaft ^*  (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CORTICOSTEROID; DAPOXETINE; NAPROXEN; OLANZAPINE; RISPERIDONE; ROFECOXIB;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG QUALITY; DRUG RESEARCH; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GERMANY; HUMAN; PHARMACY; PREMATURE EJACULATION; SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); CONFLICT OF INTEREST; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; MEDICAL ETHICS; PUBLISHING;

CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS, PHARMACY; GERMANY; HUMANS; PUBLICATION BIAS; RESEARCH SUPPORT AS TOPIC;

EID: 77952688070     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2010.0279     Document Type: Article

References (21)

1. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, et al.: The uncertainty principle and industry-sponsored research. Lancet 2000; 356: 635-638
2. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL: Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999; 282: 1453-1457 (Pubitemid 29493799)
3. Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, et al.: A study of manufacturer-supported trials of non-steroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994; 154: 157-163 (Pubitemid 24980392)
4. Yaphe J, Edman R, Knishkowy B, Herman J: The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract 2001; 18: 565-568 (Pubitemid 34026576)
5. Bero LA, Rennie D: Influences on the quality of published drug studies. Int J Technol Assess Health Care 1996; 12: 209-237 (Pubitemid 26195521)
6. Flanagin A, Carey LA, Fontanarosa PB, Phillips SG, Pace BP, Lundberg GD, et al.: Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 1998; 280: 222-224
7. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289: 454-465 (Pubitemid 36119966)
8. Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167-1170 (Pubitemid 36649048)
9. Ressing M, Blettner M, Klug SJ: Systematic literature reviews and meta-analyses: part 6 of a series on evaluation of scientific publications [Systematische Übersichtsarbeiten und Metaanalysen: Teil 6 der Serie zur Bewertung wissenschaftlicher Publikationen]. Dtsch Arztebl Int 2009; 106: 456-463
10. Sismondo S: Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials 2008; 29: 109-113
11. Golder S, Loke YK: Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol 2008; 66: 767-773
12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
13. Oxman AD, Guyatt GH: Validation of an index of the quality of review articles. J Clin Epidemiol 1991; 44: 1271-1278
14. Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 1987; 317: 141-145
15. EMA, CHMP: Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man (CPMP/EWP/205/95 Rev.3) on haematological malignancies: www.ema.europa.eu/pdfs/human/ewp/52008808en.pdf. London, 20. November 2008; Doc. Ref. EMEA/CHMP/EWP/520088/2008. Zuletzt geprüft: 8. Februar 2010.
16. Apolone G, Joppi R, Bertele' V, Garattini S: Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. Br J Cancer 2005; 93: 504-509 (Pubitemid 43079991)
17. Bertele' V, Banzi R, Capasso F, Tafuri G, Trotta F, Apolone G, et al.: Haematological anticancer drugs in Europe: any added value at the time of approval? Eur J Clin Pharmacol 2007; 63: 713-719
18. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003; 21: 1404-1411 (Pubitemid 46606423)
19. van Luijn JC, Gribnau FW, Leufkens HG: Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization. Br J Clin Pharmacol 2007; 63: 159-162
20. Trotta F, Apolone G, Garattini S, Tafuri G: Stopping a trial early in oncology: for patients or for industry? Ann Oncol 2008; 19: 1347-1353
21. Ludwig W-D, Fetscher S, Schildmann J: Teure Innovationen in der Onkologie - für alle? Der Onkologe 2009; 15: 1004-1014